Reuter, Uwe
Lucas, Christian
Dolezil, David
Hand, Austin L.
Port, Martha D.
Nichols, Russell M.
Stroud, Chad
Tockhorn-Heidenreich, Antje
Detke, Holland C. http://orcid.org/0000-0002-1316-6064
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis
https://doi.org/10.1007/s12325-022-02233-y
Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
https://doi.org/10.1007/s12325-021-01848-x
Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
https://doi.org/10.1007/s40261-021-01115-5
Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
https://doi.org/10.1007/s12325-021-01911-7
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 28 June 2021
Accepted: 31 August 2021
First Online: 20 September 2021